Prior to joining Selecta Biosciences in 2010, Dr. Cautreels was Chief Executive Officer of Solvay Pharmaceuticals, the pharmaceuticals division of the Solvay Group, in Brussels, Belgium, from 2005 until Solvay Pharmaceuticals was acquired by Abbott Laboratories in 2010. Before becoming the CEO of Solvay Pharmaceuticals, Dr. Cautreels was its Global Head of R&D from 1998.
Prior to joining Solvay, he was employed by Sanofi, Sterling‑Winthrop from 1979 to 1994, and Nycomed‑Amersham from 1994 to 1998 in a variety of R&D management positions in Europe and in the United States. Dr. Cautreels is a director of Galapagos NV in Mechelen, Belgium. He held director positions at Seres Therapeutics, Inc. in Cambridge Massachusetts from 2013 to 2016, at Innogenetics NV in Gent, Belgium from 1999 to 2006 and at ArQule Inc. in Woburn, Massachusetts each from 1999 to 2006. He was the President of the Belgian‑Luxemburg Chamber of Commerce for Russia and Belarus until June 2010. Dr. Cautreels received his Ph.D. in Chemistry, specializing in Mass Spectrometry, from the University of Antwerp (Antwerp, Belgium), and his financial and business training from the Advanced Management Program at Harvard Business School.
Prior to joining Selecta Biosciences in 2008, Dr. Johnston was Vice President of Operations for Alkermes, Inc. from 2004 to 2008, and previously served in several other roles at Alkermes, including Director of Manufacturing, from 1999 to 2004, with responsibility for process development, scale‑up, and clinical manufacturing of pulmonary and sustained-release injectable products, as well as leadership of Alkermes’ manufacturing facility in Chelsea, Massachusetts.
At Alkermes, Dr. Johnston was also a project leader and a member of steering committees for numerous products through various stages of development from Phase 1 through registration. Dr. Johnston was an original member of Advanced Inhalation Research Inc., or AIR, a private company formed in 1998 and acquired by Alkermes in 1999. Prior to joining AIR, Dr. Johnston was a lecturer in the Department of Chemical Engineering at the University of New South Wales in Sydney, Australia. He received his B.Sc. in Chemical Engineering from Queen’s University in Ontario, Canada, and his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT).
Prior to joining Selecta Biosciences in 2011, Dr. Kishimoto was Vice President of Discovery Research at Momenta Pharmaceuticals, Inc., where he served in several leadership positions from 2006 to 2011 and led a multidisciplinary research group in advancing both novel and complex generic products for inflammation, oncology, and cardiovascular disease.
He served as Senior Director of Inflammation Research at Millennium Pharmaceuticals, Inc., from 1999 to 2006, where he provided the scientific leadership for four programs in clinical development, and as an Associate Director of Research at Boehringer Ingelheim Pharmaceuticals. Dr. Kishimoto has published over 50 peer‑reviewed articles in scientific journals, including Nature, Science, Cell and The New England Journal of Medicine. Dr. Kishimoto received his B.A. from New College of the University of South Florida and his Ph.D. in Immunology from Harvard University.
Mr. Keller joined Selecta Biosciences from Abbott Laboratories in 2011. After the acquisition of Solvay Pharmaceuticals in 2010 by Abbott Laboratories, he led the integration process for five R&D and manufacturing facilities in Europe. Before the acquisition, Mr. Keller was Vice President, Head of Mergers & Acquisitions and Alliance Management at Solvay Pharmaceuticals, from 2007 to 2010, where he negotiated license and acquisition agreements in various therapeutic areas such as vaccines, neurology and cardiology.
He was the lead negotiator for the $1.5 billion fenofibrate alliance between Solvay Pharmaceuticals and Abbott Laboratories and instrumental in the $6.2 billion acquisition of Solvay Pharmaceuticals by Abbott Laboratories. Mr. Keller previously worked in management consulting at McKinsey & Company, from 2000 to 2007, and Simon Kucher & Partners, from 1998 to 2000. Mr. Keller received his M.Sci. in Industrial Engineering and Management from the Technical University of Karlsruhe in Karlsruhe, Germany.
Prior to joining Selecta Biosciences, from 2009 to 2011, Mr. Abraham was a member of Innovation Legal Group, a boutique intellectual property law firm. From 2006 to 2008, Mr. Abraham was Executive Director for Patents at Durect Corporation, a small‑cap specialty pharmaceutical company.
From 2004 to 2006, he was Senior Patent Counsel for ALZA Corporation (ALZA), a Johnson & Johnson company. Prior to working at Durect and ALZA, Mr. Abraham was employed by the law firms of Wilson Sonsini Goodrich and Rosati, and Finnegan Henderson Farabow Garrett and Dunner. Mr. Abraham also was a Patent Examiner at the United States Patent and Trademark Office. Mr. Abraham received his B.S. in Chemical Engineering from the University of Rochester and his J.D. from the George Washington University Law School.
Dr. Sands joined Selecta Biosciences in 2015. From 2014 to 2015, Dr. Sands served as the Chief Medical Officer of Targacept, Inc., now part of Catalyst Biosciences, a biopharmaceutical company focused on protease therapeutic agents, where he was responsible for designing and implementing Targacept’s clinical trials as well as providing strategic and scientific input on intellectual property matters and in‑licensing opportunities.
From 2013 to 2014, Dr. Sands was the Chief Medical Officer of Plasma Surgical, Inc., a developer of surgical and therapeutic applications, where he was responsible for strategic integrated clinical development plans and execution. From 2011 to 2013, Dr. Sands served as President of Alpha Med Solutions, LLC, a consulting firm. From 2003 to 2011, Dr. Sands served in various capacities at Solvay Pharmaceuticals, both prior to and following its acquisition by Abbott Laboratories, including Executive Vice President, Market Access, from 2008 to 2011, Senior Vice President of R&D and acting Chief Medical Officer from 2006 to 2008, and Director of Women’s Health from 2003 to 2006. Previously, Dr. Sands served as Senior Regional Medical Director, Professional and Scientific Relations, at Procter & Gamble Pharmaceuticals, was a Founding Partner and Medical Director at Innovation in Medical Education and Training, was a Managing Partner of Women’s Health Care, PC and was Chairman of the OB/GYN Department at Pottstown Memorial Medical Center in Pottstown, Pennsylvania. Dr. Sands received his B.A. in Premedical Sciences from Lehigh University and his M.D. from Hahnemann University School of Medicine.
Mr. Siewers has 30 years of experience in financial management, financial systems design and implementation, equity and debt financing and mergers and acquisitions. Prior to joining Selecta Biosciences, Mr. Siewers was an independent consultant from 2002 to 2009, providing strategic guidance and tactical implementation of accounting systems, management and regulatory reporting, internal controls, profitability and cost analysis to an array of clients ranging from startups to mid‑level companies.
Previously, Mr. Siewers held various positions in the financial services industry, including Senior Vice President and Divisional Chief Financial Officer roles within Fleet Financial Group and Senior Vice President of Putnam Investments. Mr. Siewers received his B.S. in Accounting from Marietta College and received his CPA in 1978 while working at KPMG.
Dmitry Ovchinnikov, Ph.D., has served as the General Director of Selecta’s Russian operations since 2013, and served as General Deputy Director from 2012 to 2013. Prior to joining Selecta, Dr. Ovchinnikov was a Medical Director for ZAO Sandoz (Russia), a Novartis company, from 2010 to 2012, and was responsible for medical support and compliance, clinical trials and pharmacovigilance.
Dr. Ovchinnikov was also a member of the Russia Executive Committee at Sandoz and took part in the elaboration of development strategy for the Russian branch. From 2006 to 2010, Dr. Ovchinnikov worked at Janssen-Cilag, a Johnson & Johnson company, as a Medical Manager for Russia and the Commonwealth of Independent States, and from 2004 to 2006, he served as a Clinical Research Associate for PAREXEL RUS LLC, a life sciences consulting firm and a division of PAREXEL International. Dr. Ovchinnikov received his M.S. and Ph.D. in Biochemistry/Oncology/Virology from Lomonosov Moscow State University in Moscow, Russia.